MX2019000149A - Proteinas de union a ligando 1 de muerte programada 1 (pd-l1) y metodos de uso de las mismas. - Google Patents
Proteinas de union a ligando 1 de muerte programada 1 (pd-l1) y metodos de uso de las mismas.Info
- Publication number
- MX2019000149A MX2019000149A MX2019000149A MX2019000149A MX2019000149A MX 2019000149 A MX2019000149 A MX 2019000149A MX 2019000149 A MX2019000149 A MX 2019000149A MX 2019000149 A MX2019000149 A MX 2019000149A MX 2019000149 A MX2019000149 A MX 2019000149A
- Authority
- MX
- Mexico
- Prior art keywords
- ligand
- methods
- programmed death
- binding proteins
- cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359612P | 2016-07-07 | 2016-07-07 | |
| PCT/US2017/041241 WO2018009894A1 (en) | 2016-07-07 | 2017-07-07 | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000149A true MX2019000149A (es) | 2019-09-23 |
Family
ID=59366537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000149A MX2019000149A (es) | 2016-07-07 | 2017-07-07 | Proteinas de union a ligando 1 de muerte programada 1 (pd-l1) y metodos de uso de las mismas. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11141434B2 (OSRAM) |
| EP (1) | EP3481867B1 (OSRAM) |
| JP (1) | JP7093771B2 (OSRAM) |
| KR (1) | KR102630017B1 (OSRAM) |
| CN (1) | CN109843921B (OSRAM) |
| AU (1) | AU2017292889B2 (OSRAM) |
| BR (1) | BR112019000185A2 (OSRAM) |
| CA (1) | CA3030156A1 (OSRAM) |
| DK (1) | DK3481867T3 (OSRAM) |
| EA (1) | EA201990230A1 (OSRAM) |
| ES (1) | ES3000676T3 (OSRAM) |
| IL (1) | IL264104B2 (OSRAM) |
| MA (1) | MA45595A (OSRAM) |
| MX (1) | MX2019000149A (OSRAM) |
| NZ (1) | NZ750005A (OSRAM) |
| SG (1) | SG11201900138TA (OSRAM) |
| WO (1) | WO2018009894A1 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| CN105792883B (zh) | 2013-12-05 | 2019-11-05 | 飞慕控股有限责任公司 | 利用射频电学膜击穿(rf-emb)的癌症免疫疗法 |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| EP3250142A4 (en) | 2015-01-30 | 2018-11-21 | Rfemb Holdings LLC | Radio-frequency electrical membrane breakdown for the treatment of tissues |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| IL257105B (en) | 2015-07-31 | 2022-09-01 | Univ Minnesota | Modified cells and methods of therapy |
| JP7611642B2 (ja) * | 2016-01-15 | 2025-01-10 | アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー | がんの免疫学的処置 |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| JP7181862B2 (ja) * | 2016-10-18 | 2022-12-01 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 腫瘍浸潤リンパ球および治療の方法 |
| KR20190127655A (ko) | 2016-10-19 | 2019-11-13 | 프로디자인 소닉스, 인크. | 음향학에 의한 친화성 세포 추출 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| EP3725092A4 (en) | 2017-12-14 | 2021-09-22 | FloDesign Sonics, Inc. | DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER |
| JP7558563B2 (ja) | 2018-03-15 | 2024-10-01 | ケーエスキュー セラピューティクス， インコーポレイテッド | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 |
| JP2023507432A (ja) * | 2019-12-20 | 2023-02-22 | インスティル バイオ （ユーケイ） リミテッド | 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用 |
| KR20230017786A (ko) | 2020-04-28 | 2023-02-06 | 라이엘 이뮤노파마, 인크. | 세포 배양 방법 |
| WO2024040138A1 (en) | 2022-08-17 | 2024-02-22 | Purdue Research Foundation | Universal natural killer cells derived from human pluripotent stem cells and method of use |
| EP4658310A1 (en) | 2023-01-30 | 2025-12-10 | Kymab Limited | Antibodies |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| EP0931158A1 (en) | 1996-09-06 | 1999-07-28 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| CN101584867A (zh) | 2000-10-31 | 2009-11-25 | 瑟莫迪克斯药品公司 | 提高生物活性分子传递的方法和组合物 |
| CA2497552C (en) | 2002-09-06 | 2014-05-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| WO2005035728A2 (en) | 2003-10-08 | 2005-04-21 | Wilson Wolf Manufacturing Corporation | Cell culture methods and devices utilizing gas permeable materials |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| CN101104640A (zh) * | 2006-07-10 | 2008-01-16 | 苏州大学 | 抗人pd-l1单克隆抗体制备及应用 |
| MX2011003195A (es) * | 2008-09-26 | 2011-08-12 | Dana Farber Cancer Inst Inc | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
| EP2424887B1 (en) | 2009-04-30 | 2015-09-30 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inducible interleukin-12 |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
| EP2510086A4 (en) | 2009-12-08 | 2013-05-22 | Wolf Wilson Mfg Corp | IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES |
| US20130115617A1 (en) | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
| RS61854B1 (sr) | 2010-11-12 | 2021-06-30 | Nektar Therapeutics | Konjugati il-2 dela i polimera |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| HUE031348T2 (hu) | 2011-10-21 | 2017-07-28 | Cell Medica Ltd | Eszköz sejtek aszeptikus expandálásához |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| CA2872504A1 (en) | 2012-05-18 | 2013-11-21 | Wilson Wolf Manufacturing Corporation | A static animal cell culture and cell recovery |
| JP2015519080A (ja) | 2012-06-11 | 2015-07-09 | ウィルソン ウォルフ マニュファクチャリング コーポレイションＷｉｌｓｏｎ Ｗｏｌｆ Ｍａｎｕｆａｃｔｕｒｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ | 養子細胞療法のための改良型細胞培養方法 |
| US20160010058A1 (en) | 2013-03-01 | 2016-01-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Methods of producing enriched populations of tumor-reactive t cells from tumor |
| CN111643524B (zh) | 2013-03-01 | 2023-09-05 | 美国卫生和人力服务部 | 从外周血中产生肿瘤反应性t细胞富集群的方法 |
| CN103242448B (zh) * | 2013-05-27 | 2015-01-14 | 郑州大学 | 一种全人源化抗pd-1单克隆抗体及其制备方法和应用 |
| CN118562610A (zh) | 2013-06-24 | 2024-08-30 | 威尔逊沃夫制造公司 | 用于透气性细胞培养过程的封闭系统装置和方法 |
| US10233425B2 (en) | 2013-09-16 | 2019-03-19 | The Trustees Of The University Of Pennsylvania | CD137 enrichment for efficient tumor infiltrating lymphocyte selection |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| EA036386B1 (ru) | 2014-03-20 | 2020-11-03 | Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии |
| ES2980788T3 (es) | 2014-04-10 | 2024-10-03 | H Lee Moffitt Cancer Ct & Res | Expansión mejorada de linfocitos infiltrantes de tumores para terapia celular adoptiva |
| UA123821C2 (uk) | 2014-06-11 | 2021-06-09 | Полібіосепт Гмбх | Композиція для експансії лімфоцитів in vitro |
| HUE051193T2 (hu) * | 2014-09-16 | 2021-03-01 | Innate Pharma | Gátlási reakcióút semlegesítése limfocitákban |
| ES2924709T3 (es) | 2014-10-02 | 2022-10-10 | Us Health | Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer |
| EP3034092A1 (en) | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
| JP2018504894A (ja) | 2014-12-19 | 2018-02-22 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | キメラ抗原受容体およびその使用方法 |
| JP2019532652A (ja) | 2016-10-26 | 2019-11-14 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 凍結保存腫瘍浸潤リンパ球の再刺激 |
| CA3049163A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
| EP3622055A1 (en) | 2017-05-10 | 2020-03-18 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| US11819517B2 (en) | 2017-06-05 | 2023-11-21 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
-
2017
- 2017-07-07 MA MA045595A patent/MA45595A/fr unknown
- 2017-07-07 AU AU2017292889A patent/AU2017292889B2/en active Active
- 2017-07-07 CN CN201780054791.8A patent/CN109843921B/zh active Active
- 2017-07-07 BR BR112019000185-9A patent/BR112019000185A2/pt unknown
- 2017-07-07 IL IL264104A patent/IL264104B2/en unknown
- 2017-07-07 NZ NZ750005A patent/NZ750005A/en unknown
- 2017-07-07 DK DK17740873.9T patent/DK3481867T3/da active
- 2017-07-07 EP EP17740873.9A patent/EP3481867B1/en active Active
- 2017-07-07 MX MX2019000149A patent/MX2019000149A/es unknown
- 2017-07-07 EA EA201990230A patent/EA201990230A1/ru unknown
- 2017-07-07 US US16/316,019 patent/US11141434B2/en active Active
- 2017-07-07 JP JP2019520935A patent/JP7093771B2/ja active Active
- 2017-07-07 SG SG11201900138TA patent/SG11201900138TA/en unknown
- 2017-07-07 KR KR1020197003606A patent/KR102630017B1/ko active Active
- 2017-07-07 ES ES17740873T patent/ES3000676T3/es active Active
- 2017-07-07 WO PCT/US2017/041241 patent/WO2018009894A1/en not_active Ceased
- 2017-07-07 CA CA3030156A patent/CA3030156A1/en active Pending
-
2021
- 2021-09-10 US US17/472,552 patent/US12023355B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3481867A1 (en) | 2019-05-15 |
| SG11201900138TA (en) | 2019-02-27 |
| EA201990230A1 (ru) | 2019-07-31 |
| BR112019000185A2 (pt) | 2019-04-16 |
| CN109843921A (zh) | 2019-06-04 |
| CN109843921B (zh) | 2023-05-26 |
| AU2017292889B2 (en) | 2024-09-12 |
| EP3481867B1 (en) | 2024-09-04 |
| US20220025052A1 (en) | 2022-01-27 |
| JP2019525771A (ja) | 2019-09-12 |
| US20190298770A1 (en) | 2019-10-03 |
| KR20190038825A (ko) | 2019-04-09 |
| WO2018009894A1 (en) | 2018-01-11 |
| CA3030156A1 (en) | 2018-01-11 |
| US12023355B2 (en) | 2024-07-02 |
| NZ750005A (en) | 2023-06-30 |
| KR102630017B1 (ko) | 2024-01-25 |
| AU2017292889A1 (en) | 2019-02-14 |
| DK3481867T3 (da) | 2024-11-11 |
| ES3000676T3 (en) | 2025-03-03 |
| JP7093771B2 (ja) | 2022-06-30 |
| IL264104A (en) | 2019-01-31 |
| US11141434B2 (en) | 2021-10-12 |
| IL264104B1 (en) | 2024-04-01 |
| MA45595A (fr) | 2019-05-15 |
| IL264104B2 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ750005A (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
| PH12022552122A1 (en) | Antibodies and fusion proteins that bind to ccr8 and uses thereof | |
| SA520420748B1 (ar) | أجسام مضادة للمركب الترابطي شبيه دلتا 3 /مجموعة من التمايز 3 ثنائية الخاصية | |
| MA43490A1 (fr) | Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers | |
| MA43322A1 (fr) | Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers | |
| MA44101A (fr) | Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers | |
| MA46648A1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers | |
| MA41520B2 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
| MA43457A1 (fr) | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers | |
| MA42294A (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
| MA43719B1 (fr) | Peptide à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et le cancer du poumon à petites cellules | |
| MX2025012685A (es) | Anticuerpos para claudin6 y metodos para tratar el cancer | |
| MA43328A1 (fr) | Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers | |
| MA46508A1 (fr) | Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers | |
| MA43330B1 (fr) | Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers | |
| MA46022A (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers | |
| MA44551A1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers | |
| EA202091833A1 (ru) | Пептиды и комбинации пептидов неканонического происхождения для применения в иммунотерапии различных видов рака | |
| NZ734803A (en) | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 | |
| EP4434997A3 (en) | Delivery of negatively charged proteins using cationic lipids | |
| SG163554A1 (en) | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) | |
| MX2024003355A (es) | Anticuerpos anti-cd3. | |
| MA46913B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers | |
| MA41664A1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers |